Physician profile
Jeffrey Tepler
NPI 1093771008
$1,331.55
in general payments reported to CMS, 2019-2025
16 companies · $472 in 2025
The $472 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.30 · 2020: $97.31 · 2022: $232 · 2023: $263 · 2024: $248 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $794 · Education: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $794.00 |
| Education | $188.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $227.10 | 2020-2025 | Darzalex, Imbruvica, Talvey |
| Incyte Corporation | $201.75 | 2020-2025 | Jakafi, Monjuvi, Pemazyre |
| Pfizer INC. | $119.71 | 2022-2025 | |
| Octapharma USA, INC. | $114.79 | 2022-2025 | Octagam Immune Globulin (Human), Panzyga |
| Seagen INC. | $99.00 | 2025 | |
| Celgene Corporation | $95.01 | 2022-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $76.83 | 2024-2025 | Calquence |
| Daiichi Sankyo INC. | $76.11 | 2019-2023 | Injectafer |
| E.R. Squibb & Sons, L.L.C. | $62.85 | 2022-2023 | Eliquis |
| Stemline Therapeutics INC. | $59.69 | 2025 | Orserdu |
| Amgen INC. | $51.65 | 2020 | |
| Novartis Pharmaceuticals Corporation | $47.66 | 2023-2025 | |
| Genmab U.S., INC. | $32.57 | 2023 | Epkinly |
| Lilly USA, LLC | $26.93 | 2023 | Taltz |
| Karyopharm Therapeutics INC. | $20.30 | 2024 | Xpovio |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $19.60 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Tepler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.